Skip to content
Parakho

Valiant Laboratories Ltd

NSE VALIANTLABBSE 543998

Q1 FY27

Revenue
₹73.42 Cr
Profit after tax
₹9.48 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations73.42+43.94%217.04
Other income0.85+27.01%2.89
Total income74.27+43.72%219.94
Employee benefit expense1.22+2.59%5.00
Finance costs0.08+4.37%0.26
Depreciation & amortisation0.55+6.34%2.26
Total expenses61.55+25.01%212.39
Profit before tax12.73+420.40%7.55
Tax expense3.25+415.66%2.00
Profit after tax9.48+422.05%5.55
Total comprehensive income9.48+422.05%5.54
Earnings per share
Earnings per share, basic₹1.75₹1.02
Earnings per share, diluted₹1.75₹1.10

Q1 FY27 — from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Valiant Laboratories Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 33 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 29 Sept 2026.